An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date.

Expert Opinion on Pharmacotherapy
Júlia Sellarès-NadalBenito Almirante

Abstract

Introduction: Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are prevalent nosocomial infections with a worrisomely increasing prevalence of multidrug-resistant causative organisms, including those with resistance to carbapenems. The addition of relebactam, a β-lactamase inhibitor, to imipenem treatment restores the antimicrobial activity against the most of multidrug-resistant Gram-negative bacteria, including some carrying β-lactamase enzyme-type carbapenemases.Areas covered: The aim of this article is to summarize the current evidence regarding imipenem/relebactam for the treatment of HAP/VAP. The authors discuss its chemistry, pharmacokinetics/pharmacodynamics, microbiology, tolerance and clinical efficacy. The results of clinical trials have demonstrated an efficacy of imipenem/relebactam similar to that of its comparator for the treatment of patients with HAP/VAP. Different studies have also shown its good safety profile, which is better than that of the combination of other β-lactams with other antibiotics.Expert opinion: This drug should be incorporated as a new therapeutic option for the treatment of patients with HAP/VAP, especially as an alternative treatment in patients with confirmed in...Continue Reading

References

Jul 1, 1985·Reviews of Infectious Diseases·H KroppF M Kahan
Mar 22, 2002·Intensive Care Medicine·Corinne AlbertiRoger Le Gall
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Sep 26, 2006·The Journal of Antimicrobial Chemotherapy·A C RodloffA Torres
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
May 28, 2008·American Journal of Infection Control·Evelina N Lagamayo
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ronald N Jones
Sep 10, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Timothy F Jones
Jun 10, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil GuptaAlexander J Kallen
Aug 24, 2011·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
Jan 26, 2013·Annals of the New York Academy of Sciences·David M Shlaes
May 23, 2013·The Journal of Antimicrobial Chemotherapy·David M LivermoreShazad Mushtaq
Jan 18, 2014·Bioorganic & Medicinal Chemistry Letters·Timothy A BlizzardMilton L Hammond
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Sep 10, 2014·Journal of Pharmacy Practice·Kurt A Wargo, Jonathan D Edwards
Sep 28, 2014·Journal of Medical Microbiology·Raquel Cavalcanti DantasRosineide Marques Ribas
May 16, 2015·Critical Care Medicine·Lila BouadmaUNKNOWN OUTCOMEREA Study Group
May 28, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaJohn Quale
Jul 16, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Andre C KalilJan L Brozek
Aug 10, 2016·Antimicrobial Agents and Chemotherapy·Christopher LucastiAmanda Paschke
Oct 22, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M WeinerDawn M Sievert
Nov 12, 2016·JAMA : the Journal of the American Medical Association·Mark L MeterskyNoel Eldridge
Mar 23, 2017·European Journal of Medicinal Chemistry·Mohammed I El-GamalAmany Bahaaeldin
Jun 5, 2017·Seminars in Respiratory and Critical Care Medicine·Taryn E Hassinger, Robert G Sawyer
Jul 28, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J DobiasP Nordmann
Aug 30, 2017·Antimicrobial Agents and Chemotherapy·Olga LomovskayaMichael N Dudley
Apr 4, 2018·Antimicrobial Agents and Chemotherapy·Krisztina M Papp-WallaceRobert A Bonomo
May 16, 2018·Antimicrobial Agents and Chemotherapy·Suzannah M Schmidt-MalanRobin Patel
Jan 8, 2019·Expert Opinion on Pharmacotherapy·Joaquin BurgosBenito Almirante
Jan 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Ilias KaraiskosHelen Giamarellou
Mar 3, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Irene GalaniUNKNOWN Study Collaborators
Jun 9, 2019·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Young Ran Lee, Caitlin Elizabeth Burton
Aug 11, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Johann MotschAmanda Paschke
Sep 12, 2019·CPT: Pharmacometrics & Systems Pharmacology·Pratik BhagundeMatthew L Rizk
Jan 15, 2020·Current Infectious Disease Reports·Mandee NovalEmily Heil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

© 2021 Meta ULC. All rights reserved